Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Steven A. Miles et al.|The Lancet Oncology|2012Cited by 550
Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)Thomas Helmberger, Alessandro Vit, Rita Golfieri et al.|CardioVascular and Interventional Radiology|2020Cited by 83
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT studyFrank T. Kolligs, Alessandro Vit, Dirk Arnold et al.|JHEP Reports|2022Cited by 46
ITF-2 Is Disrupted via Allelic Loss of Chromosome 18q21, and ITF-2B Expression Is Lost at the Adenoma-Carcinoma TransitionAndreas Herbst, Frank T. Kolligs|Gastroenterology|2009Cited by 24
Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cellsBenjamin Hirschi, Frank T. Kolligs|Molecular Cancer|2014Cited by 21